Envista (NYSE:NVST) Research Coverage Started at Barclays

Barclays began coverage on shares of Envista (NYSE:NVST) in a research note issued to investors on Monday, Marketbeat.com reports. The brokerage issued an overweight rating and a $24.00 target price on the stock.

A number of other research analysts also recently weighed in on NVST. Mizuho set a $19.00 price objective on shares of Envista in a research report on Monday, November 3rd. Robert W. Baird set a $27.00 price target on Envista in a report on Friday, October 31st. Weiss Ratings reiterated a “sell (d)” rating on shares of Envista in a research report on Monday. Wall Street Zen upgraded Envista from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 1st. Finally, Stifel Nicolaus set a $25.00 target price on Envista in a research report on Thursday, October 30th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, eight have issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $21.54.

Envista Trading Up 7.2%

Envista stock opened at $22.11 on Monday. The firm has a market cap of $3.64 billion, a PE ratio of 245.69, a P/E/G ratio of 1.01 and a beta of 1.02. Envista has a 12 month low of $14.22 and a 12 month high of $22.68. The stock’s 50 day simple moving average is $20.11 and its two-hundred day simple moving average is $20.07. The company has a current ratio of 2.37, a quick ratio of 2.02 and a debt-to-equity ratio of 0.47.

Envista (NYSE:NVST) last posted its earnings results on Wednesday, October 29th. The company reported $0.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.27 by $0.05. The firm had revenue of $669.90 million during the quarter, compared to analysts’ expectations of $639.49 million. Envista had a net margin of 0.58% and a return on equity of 5.90%. The business’s revenue was up 11.5% compared to the same quarter last year. During the same period in the previous year, the business posted $0.12 EPS. Analysts anticipate that Envista will post 1 earnings per share for the current year.

Institutional Trading of Envista

Several large investors have recently made changes to their positions in the company. Farther Finance Advisors LLC lifted its holdings in Envista by 317.6% in the 3rd quarter. Farther Finance Advisors LLC now owns 1,349 shares of the company’s stock valued at $27,000 after purchasing an additional 1,026 shares in the last quarter. Caitong International Asset Management Co. Ltd lifted its stake in shares of Envista by 16,711.1% in the third quarter. Caitong International Asset Management Co. Ltd now owns 1,513 shares of the company’s stock worth $31,000 after buying an additional 1,504 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Envista by 73.1% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 2,248 shares of the company’s stock worth $44,000 after buying an additional 949 shares in the last quarter. SJS Investment Consulting Inc. grew its stake in Envista by 10,356.5% during the 3rd quarter. SJS Investment Consulting Inc. now owns 2,405 shares of the company’s stock valued at $49,000 after acquiring an additional 2,382 shares in the last quarter. Finally, EverSource Wealth Advisors LLC grew its stake in Envista by 378.0% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,414 shares of the company’s stock valued at $47,000 after acquiring an additional 1,909 shares in the last quarter.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.